Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pyrrolobenzodiazepine (PBD) dimers are a class of highly potent, sequence-selective DNA cross-linking agents that bind within the minor groove of DNA. These molecules form covalent interstrand cross-links, primarily at guanine bases, disrupting DNA replication and transcription. They are utilized as cytotoxic payloads in antibody-drug conjugates (ADCs) and as stand-alone antitumor agents due to their potent cytotoxic effects, even against resistant tumor cells.
Sequence-selective interstrand covalent cross-linking of DNA via minor groove binding, leading to replication and transcription inhibition.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA Minor Groove Cross-Linking Agent (Pyrrolobenzodiazepine Dimer).